Table 2 Risks and risk differences of 30-day mortality categorized by marker positivity for soluble tumor necrosis factor receptor-1 (sTNFR1), interleukin-8 (IL8), and angiopoietin-2 (Ang2), in the derivation (N = 200) and validation (N = 200) cohorts. Standardized risks and risk differences are reported for the derivation cohort, adjusted for age, cirrhosis, immunocompromised state, septic shock at presentation, and mechanical ventilation at presentation. Crude risks and risk differences are reported for the validation cohort. The IL8 analysis is limited to immunocompetent patients (N = 105 in derivation cohort, N = 173 in validation cohort)
From: Plasma sTNFR1 and IL8 for prognostic enrichment in sepsis trials: a prospective cohort study
Marker and site | Number (%) of subjects above threshold | 30-day mortality (95% CI) if below threshold | 30-day mortality (95% CI) if above threshold | Risk difference of 30-day mortality (95% CI) if above threshold | p |
|---|---|---|---|---|---|
sTNFR1 > 8861 pg/ml | |||||
 Derivation | 93 (46.5%) | 30.4% (21.6, 39.2) | 52.0% (42.3, 61.7) | 21.6% (8.1, 35.2) | 0.002 |
 Validation | 67 (33.5%) | 21.1% (14.1, 28.0) | 38.8% (27.1, 50.5) | 17.8% (4.2, 31.3) | 0.010 |
IL8 > 94 pg/ml | |||||
 Derivation | 57 (54.3%) | 23.2% (11.8, 34.6) | 40.9% (29.8, 52.0) | 17.7% (1.6, 33.8) | 0.031 |
 Validation | 68 (39.3%) | 18.9% (11.9, 25.8) | 44.1% (32.3, 55.9) | 27.0% (13.2, 40.8) | < 0.001 |
Ang2 > 9761 pg/ml | |||||
 Derivation | 139 (69.5%) | 25.8% (14.6, 37.1) | 47.1% (39.3, 54.9) | 21.3% (7.3, 35.3) | 0.003 |
 Validation | 127 (63.5%) | 19.2% (10.2, 28.2) | 31.5% (23.4, 39.6) | 12.3% (0.2, 24.4) | 0.046 |